AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 32115328
Drug: Surgeon administered
RxNorm normalized name: sturgeon, unspecified preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgeon administered ACB (group 2)
Trial: 34982493
Drug: 20 mg/day
RxNorm normalized name: futibatinib 20 mg/day (4 mg x 5) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg/day oral isotretinoin
Trial: 35101419
Drug: Standard-dose warfarin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose warfarin
Trial: 36449420
Drug: Deferiprone (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deferiprone (15 mg/kg twice daily)
Trial: 33578001
Drug: Stereotactic radiosurgery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stereotactic radiosurgery (SRS) administered ≤4 weeks postoperatively
Trial: 33578001
Drug: Stereotactic radiosurgery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stereotactic radiosurgery (SRS) administered >4 weeks postoperatively
Trial: 32152170
Drug: CBD 20
RxNorm normalized name: MENTHOL 0.06 g in 1 g TOPICAL GEL [SOMBRA PLUS CBD 2000MG COOL THERAPY]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CBD 20 mg/kg/day
Trial: 35083234
Drug: Intravitreal conbercept
RxNorm normalized name: Dexamethasone Intravitreal Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal conbercept injection
Trial: 33152282
Drug: Angiogenesis inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Angiogenesis inhibitors
Trial: 32524612
Drug: Labeled glass
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Labeled glass (340-ml glasses of beer or wine)
Trial: 32524612
Drug: Plain glass
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plain glass (control, 340-ml glasses of beer or wine)
Trial: 33625666
Drug: Yoga therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yoga therapy for 3 months in addition to pharmacological treatment
Trial: 32281269
Drug: Physical therapy‐led
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical therapy‐led pathway
Trial: 39306665
Drug: Piroxicam (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piroxicam (20 mg)
Trial: 35283116
Drug: Synthetic ACTH
RxNorm normalized name: ACTH
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Synthetic ACTH (1 mg)
Trial: 35283116
Drug: Betamethasone (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Betamethasone (6 mg)
Trial: 32150492
Drug: Epinephrine CFC
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epinephrine CFC MDI (220 μg/inhalation)
Trial: 35428609
Drug: Aprepitant 125
RxNorm normalized name: aprepitant 125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aprepitant 125 mg/kg on day 1, followed by 80 mg/kg on days 2 and 3, plus granisetron 3 mg/m2 on day 1 and dexamethasone on days 1 to 3
Trial: 35428609
Drug: Aprepitant 125
RxNorm normalized name: aprepitant 125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aprepitant 125 mg/kg on day 1 and placebo on days 2 and 3, plus granisetron 3 mg/m2 on day 1 and dexamethasone on days 1 to 3
Trial: 32537707
Drug: Multi-component training
RxNorm normalized name: Parasedge Multi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multi-component training (including dual-task, dynamic balance, endurance and strength exercises) for 16 weeks (twice per week for 45–60 min)
Trial: 38456441
Drug: Multiple Daily
RxNorm normalized name: Multivitamin Oral Tablet [MULTIPLE DAILY W/BETA]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple Daily Injections (MDI)
Trial: 35567889
Drug: Probiotic (Vivomix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic (Vivomix 112 billion, one capsule a day for 16 weeks)
Trial: 32911306
Drug: teriflunomide 14
RxNorm normalized name: teriflunomide 14 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: teriflunomide 14 mg/14 mg
Trial: 36454520
Drug: Drug-related readmission
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug-related readmission within 12 months post-discharge
Trial: 36454520
Drug: Potentially preventable
RxNorm normalized name: Potentilla discolor whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Potentially preventable drug-related revisits
Trial: 32649736
Drug: Entecavir treatment
RxNorm normalized name: Entecavir
DrugBank: Entecavir (DB00442)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Entecavir treatment
Trial: 35791646
Drug: DBPR108 +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DBPR108 + metformin
Trial: 32631447
Drug: 1:1 delta-9-tetrahydrocannabinol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1:1 delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) preparation.
Trial: 32631447
Drug: Placebo (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (oral solution).
Trial: 33676886
Drug: Personalized digital
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Personalized digital and human direct oral anticoagulant adherence intervention (medication management smartphone app, daily app-based reminders, adaptive text messaging, and phone-based counseling for severe nonadherence)
Trial: 32838353
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no antiviral medication)
Trial: 34127032
Drug: Robotic rehabilitation
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Robotic rehabilitation using G-EO system
Trial: 35337743
Drug: Landiolol (0.5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Landiolol (0.5, 1, 2, 5, and 10 μg/kg/min)
Trial: 33316626
Drug: EPA 4
RxNorm normalized name: krill oil/omega-3/dha/epa 45 mg-45 mg ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EPA 4 g/d
Trial: 33316626
Drug: EPA 1
RxNorm normalized name: thiotepa 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EPA 1 g/d
Trial: 33316626
Drug: EPA 2
RxNorm normalized name: docosahexaenoic acid/epa 250 mg-100 mg ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EPA 2 g/d
Trial: 35410590
Drug: PartoMa intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PartoMa intervention (co-created clinical practice guidelines and low-dose, high-frequency training)
Trial: 33431052
Drug: High-dose saccharin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose saccharin supplementation (administered in capsules twice daily for 2 weeks)
Trial: 33431052
Drug: High-dose saccharin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose saccharin supplementation
Trial: 32004499
Drug: Type-IV resistant
RxNorm normalized name: collagen type I
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Type-IV resistant starches (RS4s), specifically crystalline and phosphate cross-linked starch structures, administered at a dose of 35 g/day.
Trial: 35991892
Drug: Intravenous hydromorphone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous hydromorphone PCA (0.05 mg/h with 0.2 mg on-demand)
Trial: 35991892
Drug: Intravenous hydromorphone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous hydromorphone PCA
Trial: 34533832
Drug: 1% metformin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% metformin gel plus platelet-rich fibrin (PRF)
Trial: 33543637
Drug: Medication review
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication review with follow-up
Trial: 32221052
Drug: Metronomic chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metronomic chemotherapy
Trial: 36261752
Drug: Palliative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palliative treatment
Trial: 32726003
Drug: Huoxiang Zhengqi
RxNorm normalized name: HYPOCHLOROUS ACID 100 mg in 500 mL EXTRACORPOREAL LIQUID [Huoting slight acid hypochlorite disinfectant]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Huoxiang Zhengqi Oral Liquid and Jinhao Jiere Granules
Trial: 33581920
Drug: QVLP (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QVLP (30 μg HA/strain) from three sequential lots
Trial: 33258553
Drug: Tofacitinib 11
RxNorm normalized name: tofacitinib 11 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tofacitinib 11 mg XR daily
Trial: 36427600
Drug: Levonorgestrel 52‐mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levonorgestrel 52‐mg intrauterine device
Trial: 34033266
Drug: Diazepam nasal
RxNorm normalized name: diazepam Nasal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam nasal spray
Trial: 32065672
Drug: Diazepam rectal
RxNorm normalized name: diazepam Rectal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam rectal gel
Trial: 33580745
Drug: MR-OA (90/30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MR-OA (90/30 mg orlistat/mg acarbose)
Trial: 33580745
Drug: MR-OA (120/40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MR-OA (120/40 mg orlistat/mg acarbose)
Trial: 33580745
Drug: Conventional orlistat
RxNorm normalized name: Orlistat
DrugBank: Orlistat (DB01083)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conventional orlistat (Xenical, 120 mg)
Trial: 33421559
Drug: Intravenous TXA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous TXA (2 g)
Trial: 33543897
Drug: Oxytocin 5
RxNorm normalized name: oxytocin 5 UNT/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxytocin 5 units intravenous alone
Trial: 33543897
Drug: Oxytocin plus
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxytocin plus carboprost 0.25 mg intramuscular
Trial: 33605002
Drug: Intralesional botulinum
RxNorm normalized name: Clostridium botulinum
DrugBank: Clostridium botulinum (DB14223)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intralesional botulinum toxin type-A (BTX-A) injection
Trial: 35120640
Drug: Intermittent treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent treatment (4-days-on and 3-days-off regimen)
Trial: 33790017
Drug: Deworming treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deworming treatment (two to three additional years)
Trial: 35939083
Drug: Psilocybin-assisted therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psilocybin-assisted therapy (n = 27)
Trial: 34331678
Drug: Daridorexant 200
RxNorm normalized name: Daridorexant
DrugBank: Daridorexant (DB15031)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Daridorexant 200 mg
Trial: 32744034
Drug: RBX Chinese
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RBX Chinese herbal tablets (CHT)
Trial: 33436442
Drug: Intravenous dexmedetomidine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous dexmedetomidine, intravenous magnesium, intrathecal morphine, quadratus lumborum blocks, paravertebral nerve blocks, continuous local anesthetic wound infiltration, postoperative interpleural local anesthesia
Trial: 33436442
Drug: Intravenous lidocaine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous lidocaine, ketamine, dexamethasone, gabapentinoids
Trial: 33894832
Drug: Vagus nerve
RxNorm normalized name: SUS SCROFA VAGUS NERVE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vagus nerve stimulation (0.8 mA, 100 μs, 30 Hz stimulation pulses, lasting 0.5 s) paired with rehabilitation (6 weeks of in-clinic therapy, three times per week, followed by home exercise programme)
Trial: 36229710
Drug: Other oral
RxNorm normalized name: Ether
DrugBank: Diethyl ether (DB13598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other oral SERDs
Trial: 32762340
Drug: OM-89 immunotherapy
RxNorm normalized name: Sudafed OM
DrugBank: Oxymetazoline (DB00935)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: OM-89 immunotherapy (6 mg), once daily for 3 months
Trial: 32762340
Drug: Placebo, once
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, once daily for 3 months
Trial: 34032803
Drug: Guided internet
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guided internet delivered cognitive behavioural treatment (CBT) for insomnia
Trial: 34489388
Drug: Opioid medications
RxNorm normalized name: OPIOIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Opioid medications
Trial: 34464304
Drug: Preoperative physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative physical therapy education program
Trial: 34112719
Drug: MRI (absent/equivocal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MRI (absent/equivocal signal in the posterior limb of the internal capsule)
Trial: 33674187
Drug: Chemotherapy in
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy in 6-IHC score 'High' risk group
Trial: 33674187
Drug: No chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No chemotherapy in 6-IHC score 'Low' risk group
Trial: 32678376
Drug: Weighted blanket
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weighted blanket during chemotherapy infusion
Trial: 32678376
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no weighted blanket during chemotherapy infusion)
Trial: 32989261
Drug: Low-intensity shockwave
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-intensity shockwave therapy (LiST) - 5000 shockwaves per session with energy flux density 0.1 mJ/mm2, 6 sessions (once/week)
Trial: 32989261
Drug: Sham treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham treatment - 5000 shockwaves from a visually identical sham probe, 6 sessions (once/week)
Trial: 33188493
Drug: Epidural dexmedetomidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural dexmedetomidine (0.1% ropivacaine with 0.5 µg/mL dexmedetomidine)
Trial: 35122766
Drug: Higher induction
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher induction regimen (adalimumab 160 mg at weeks 0, 1, 2, and 3)
Trial: 35122766
Drug: Standard induction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard induction regimen (adalimumab 160 mg at week 0 and 80 mg at week 2)
Trial: 32198301
Drug: Mesenchymal stem
RxNorm normalized name: Human mesenchymal stem cell
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mesenchymal stem cell (MSC) therapy
Trial: 33762031
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D sufficient (25(OH)D ≥ 30 ng/mL)
Trial: 33762031
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D levels above 27.16-30.69 ng/mL
Trial: 37767823
Drug: Bright light
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bright light therapy (BLT)
Trial: 36753698
Drug: Placebo twice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo twice a day
Trial: 33148481
Drug: Enalapril alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril alone (10 mg enalapril daily)
Trial: 33852498
Drug: High-dose epidural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose epidural fentanyl (≥100 μg)
Trial: 36308037
Drug: Standardized skin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardized skin care regimen including once daily leave-on product application (lipid content 21%)
Trial: 32394657
Drug: Warming acupuncture,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warming acupuncture, 50 min each treatment, once daily, at the interval of 1 day after 4-day treatment, until ovulatory stage.
Trial: 32394657
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group received nuangong yunzi capsules, 3 capsules each time, three times a day, until ovulatory stage.
Trial: 36083983
Drug: Outdoor residual
RxNorm normalized name: Cleartime Indoor & Outdoor Allergies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Outdoor residual spraying (ORS) with a capsule suspension of lambda-cyhalothrin for two days in October.
Trial: 34887183
Drug: Caudal epidural
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caudal epidural block (CEB) using 0.5 mg/kg of 0.125% bupivacaine (Marcaine)
Trial: 32195729
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no additional treatment)
Trial: 33743111
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of four serum miRNAs (miR-4257, miR-6785-5p, miR-187-5p, and miR-5739)
Trial: 32805278
Drug: Health-related image
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Health-related image included on dietary supplement packaging
Trial: 35311937
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid (1 g in 100-mL intravenous bolus loading dose, followed by 1 g in 250-mL infusion within 8 hours of ICH onset)
Trial: 36029489
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D supplementation (0.25-0.5 mg/day) for eight weeks
Trial: 34724213
Drug: 2.0% PVP-I
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.0% PVP-I nasal spray
Trial: 32646501
Drug: unripe Rubus
RxNorm normalized name: Rubus chamaemorus seed oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: unripe Rubus coreanus (uRC) 600 mg daily for 12 weeks
Trial: 34170489
Drug: Treatment for
RxNorm normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment for anorexia nervosa
Trial: 33837377
Drug: Drugs targeting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drugs targeting IFNAR2
Trial: 35246396
Drug: Intranasal low-level
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal low-level laser therapy (LLLT)
Trial: 35246396
Drug: Acupuncture treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture treatment (AT)
Trial: 32783178
Drug: Palbociclib plus
RxNorm normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Palbociclib plus endocrine therapy
Trial: 32635503
Drug: Cod protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cod protein hydrolysate (CPH), 4 g daily for 8 weeks
Trial: 35864302
Drug: Cinnarizine 20
RxNorm normalized name: cinnarizine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cinnarizine 20 mg
Trial: 33108633
Drug: Oral siponimod
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral siponimod 2 mg (initial dose titration over 6 days)
Trial: 32557338
Drug: Stronger postoperative
RxNorm normalized name: Strongid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stronger postoperative analgesia (75/650 mg tramadol with paracetamol every 8 hours)
Trial: 34031117
Drug: Thrice-weekly haemodialysis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrice-weekly haemodialysis (standard HD group)
Trial: 33902372
Drug: Paracetamol 1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol 1000 mg IV infusion
Trial: 33902372
Drug: Pethidine 50
RxNorm normalized name: Pethidine
DrugBank: Meperidine (DB00454)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pethidine 50 mg IV infusion
Trial: 36383222
Drug: Drug-free DMN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug-free DMN
Trial: 34226203
Drug: 6-week behaviour
RxNorm normalized name: perampanel
DrugBank: Perampanel (DB08883)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 6-week behaviour change intervention (weekly sessions with a physiotherapist)
Trial: 32615727
Drug: Placebo (equivalent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (equivalent vehicle), administered for 12 weeks
Trial: 32506861
Drug: Basic treatment
RxNorm normalized name: Basic Fuchsin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basic treatment with prednisone
Trial: 35485939
Drug: Weekly digital
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly digital interventions assessing treatment adherence
Trial: 32501212
Drug: Mandibular advancement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mandibular advancement appliance (MAA) therapy
Trial: 33960006
Drug: Active repetitive
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active repetitive transcranial magnetic stimulation (rTMS) with cognitive processing therapy (CPT+A)
Trial: 33960006
Drug: Sham repetitive
RxNorm normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham repetitive transcranial magnetic stimulation (rTMS) with cognitive processing therapy (CPT+A)
Trial: 34252909
Drug: Ketamine treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine treatment
Trial: 34704480
Drug: Infliximab (anti-tumor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infliximab (anti-tumor necrosis factor antibody)
Trial: 34704480
Drug: Antibiotics and/or
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotics and/or seton drainage
Trial: 34704480
Drug: Therapy directed
RxNorm normalized name: Chimeric Antigen Receptor immunotherapy directed against CLL-1 and CD33
DrugBank: CLL1-CD33 compound chimeric antigen receptor T cells (DB18568)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapy directed against intestinal inflammation